About Us

Leslie has served as our Chief Executive Officer since November 2014 and was elected Chair in 2022. She joined the company from Warburg Pincus, a private equity firm, where she was an Executive in Residence from March 2012 to March 2014. Prior to that, she served in several roles at Lutonix (acquired by CR Bard), a medical device company, from January 2010 to February 2012, including as Executive Vice President, and as Chief Business Officer of AccessClosure (acquired by Cardinal Health), a medical device company, from September 2006 to June 2009. She also previously held positions with FoxHollow Technologies (acquired by ev3/Covidien), a manufacturer of devices to treat peripheral artery disease, Cytyc, a diagnostic and medical device company, Pro-Duct Health (acquired by Cytyc), a medical device company, and Guidant, a cardiovascular medical device company. She serves on the board of directors of the Medical Device Manufacturers Association. Leslie holds a B.S. degree from Northwestern University and an M.B.A. from The Haas School of Business, UC Berkeley.

Keith has been a leader in the medical technology industry for more than 35 years. He served as Chairman of the Board of Nevro Corporation (NVRO) from 2019 through April 2025 when the company was acquired by Globus Medical, Inc, previously serving as Nevro’s President and CEO from 2019 through April 2023. Prior to Nevro, he was named President and CEO of Thoratec Corp. (THOR) for the second time in 2014. He led the company’s return to growth, a 2.5x increase in company value and its $3.4 billion acquisition by St. Jude Medical in 2015. He previously served as the CEO, President and Director of Conceptus, Inc. (CPTS) from 2011 to 2013, where he took the company from negative sales growth to over 20% growth, tripled EBIDTA, and led the company’s sale to Bayer Healthcare for over $1.1 billion, a 3x increase in the company’s value prior to his arrival. From 2007 to 2011, he served as Managing Director for TPG Biotech, the $1.1 billion venture capital arm of the private equity firm Texas Pacific Group (TPG) where he co-led the medical device investment initiatives. Prior to TPG, he served as CEO, President and Director of Thoratec from 1996 to 2006, increasing the company’s market value more than 12x, and leading the company from no revenue to more than $200 million in annual revenues. Prior to Thoratec, he held a number of commercial and general management roles with companies including SulzerMedica and American Hospital Supply Corp. He currently serves as Vice Chairman of Alcon Inc. (ALC) and on the Board of Directors of MiniMed Group, Inc. (MMED). In addition to his prior service on Nevro’s Board of Directors, he is a former member of the Board of Directors of ViewRay, Inc. (VRAY), Intuitive Surgical, Inc. (ISRG), Kyphon, Inc. (KYPH), Zeltiq (which was acquired by Allergan in 2017), and a number of private medical technology companies.

Karen is a healthcare industry veteran with a focus on chronic disease management, data analytics, and home based care. She has been an active board member for public and private medical device and diagnostics companies for over a decade. She currently sits on the boards of ResMed (NYSE:RSMD), EBR Systems (ASX:EBR), VIDA Diagnostics, and Huma.AI, and formerly served on the board of Tivic Health Systems (NASDAQ:TIVC). Most recently, she was CEO of Sandstone Diagnostics, a life science tools company focused on increased access to high-quality diagnostic testing. Previously, she founded and served as CEO at Amira Medical until its sale to Roche Diabetes Care. She started her career at LifeScan, where she managed a variety of functions and ultimately executed the sale of the company to Johnson & Johnson.

Patrick is a Special Limited Partner of Warburg Pincus (NYSE:WPCA). He joined Warburg Pincus in 1990 and in his 29 years at Warburg Pincus, he has focused on investments in the technology and health care services fields. Prior to joining Warburg Pincus, he was the Vice President of Cove Capital Associates, a private merchant banking partnership, and prior to that a partner with private equity firm, Acadia Partners. He is a Director of Intelligent Medical Objects, a private healthcare software company. In addition, he serves on the Board of Directors at Stamford Health System, a nonprofit community hospital in Connecticut. He graduated from the University of Pennsylvania with a B.A. in chemistry, and holds a B.S. in economics from the Wharton School at the University of Pennsylvania.

Brent is Chairman of the Movella Holdings Inc. board, a company specializing in movement digitization, and a member of the Thriveworks board, a private company that provides mental health services. Brent most recently served as Chairman and Chief Executive Officer of Vocera Communications, a global provider of clinical communication and workflow solutions, until its acquisition by Stryker in 2022. Including his role as Chairman and CEO, he spent more than 20 years in various leadership positions at Vocera, including President and Chief Operating Officer and Vice President of Marketing and Business Development. Earlier in his career, he held leadership roles at 3Com Corporation and worked as a strategy consultant for Monitor Company, Inc. Brent holds a B.S. from the University of Michigan and an M.B.A. from the Stanford University Graduate School of Business. He was also a gold medalist member of the 1988 U.S. Olympic swimming team.

Mr. O’Boyle has served on the board of directors of iRhythm Technologies, Inc., a digital healthcare company, since July 2025, and on the board of directors of Carlsmed, Inc., a medical technology company specializing in personalized spine surgery solutions, since September 2024. Previously, Kevin served on the board of directors of Nevro Corp., a global medical device company, from March 2019 through April 2025 when the company was acquired by Globus Medical, Inc. He also served as Chairman of the board of directors of GenMark Diagnostics, Inc., a diagnostics company until its acquisition by Roche in May 2021. Additionally, Kevin also served on the boards of directors of Sientra, Inc., a medical aesthetics company, from May 2014 to June 2023, Wright Medical Group N.V. (acquired by Stryker), a global medical device company, from November 2015 to November 2020, Zeltiq Aesthetics, Inc. (acquired by Allergan), a medical aesthetics company, from July 2011 to April 2017, and Durata Therapeutics, Inc. (acquired by Actavis), a pharmaceutical company, from May 2012 to November 2014. Previously, Kevin served as Senior Vice President and Chief Financial Officer of Advanced Biohealing Inc., a medical device company, from December 2010 until it was acquired in July 2011. Prior to that, he served as Chief Financial Officer of NuVasive, Inc., a medical device company, from January 2003 to December 2009. Earlier in his career, he served in various leadership positions during his six years with ChromaVision Medical Systems, Inc. Kevin holds a B.S. in Accounting from the Rochester Institute of Technology.

Karen serves on the boards of AtriCure, Embecta and privately held WS Audiology, in addition to being a Senior Advisor to EQT Group. She previously served on the boards of Cantel Medical, Nevro and ViewRay. In her most recent operating role, she was Executive Vice President and CEO for the $6 billion Global Animal Health, Medical and Dental Surgical Group at Henry Schein. She was previously a Senior Vice President at Boston Scientific and President of its $1 billion Urology and Pelvic Health business. Her earlier career experience included 17 years at Johnson & Johnson in various sales, marketing, market development and general management roles. She earned her B.S. in Business Administration with honors from the University of Florida and has completed executive education coursework at the UCLA Anderson School of Business.